Also known as: Medpace
Medpace is a global full-service clinical contract research organization that provides Phase I-IV clinical development services to biotechnology, pharmaceutical, and medical device companies. The company emphasizes a therapeutically focused and integrated CRO model.
Dosing has begun in a Phase 1 trial of ZI-MA4-1, the first MAGE-A4-targeting TCR-NK cell therapy for solid tumours, with initial data expected from mid-2026. The off-the-shelf therapy is being evaluated at two UK sites.
AI could compress drug development from 10-15 years to as little as six years, accelerating discovery and reducing late-stage trial failures. However, clinical trial execution remains heavily dependent on human oversight, with AI estimated to cut costs only 10-15% while facing regulatory and liability constraints. Major pharma companies like Gilead are investing in AI research centers despite practical limitations in trial implementation.
Eight drug development inputs and services companies reported mixed Q4 earnings, with revenues beating consensus estimates by 1.5% as a group. Charles River Laboratories, Medpace, Fortrea, and Repligen showed varied performance.
The global drug discovery services market is valued at $22.04 billion in 2025 and is forecast to reach $75.13 billion by 2034, growing at a 14.6% CAGR from 2026-2034, driven by rising industry demand and technological advancements.
